KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Research & Development (2019 - 2025)

Royalty Pharma's Research & Development history spans 7 years, with the latest figure at $50.5 million for Q4 2025.

  • For Q4 2025, Research & Development rose 10000.0% year-over-year to $50.5 million; the TTM value through Dec 2025 reached $452.0 million, up 22500.0%, while the annual FY2025 figure was $452.0 million, 22500.0% up from the prior year.
  • Research & Development for Q4 2025 was $50.5 million at Royalty Pharma, down from $101.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $250.0 million in Q2 2025 and bottomed at $500000.0 in Q1 2023.
  • The 5-year median for Research & Development is $14.3 million (2021), against an average of $44.2 million.
  • The largest annual shift saw Research & Development plummeted 99.5% in 2023 before it soared 49900.0% in 2025.
  • A 5-year view of Research & Development shows it stood at $103.8 million in 2021, then plummeted by 51.36% to $50.5 million in 2022, then plummeted by 99.01% to $500000.0 in 2023, then changed by 0.0% to $500000.0 in 2024, then skyrocketed by 10000.0% to $50.5 million in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Research & Development are $50.5 million (Q4 2025), $101.0 million (Q3 2025), and $250.0 million (Q2 2025).